Monopar Expands Clinical Team with Appointment of Laura Kelly as Director of Clinical Operations
February 18, 2021 07:00 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics...
Monopar Announces First Patient Dosed in its Phase 2b/3 VOICE Trial Evaluating Validive® for the Prevention of Chemoradiotherapy-Induced Severe Oral Mucositis (SOM) in Oropharyngeal Cancer (OPC)
February 16, 2021 07:30 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics...
Monopar宣布其评估Validive®预防化疗引起口咽癌（OPC）患者重度口腔粘膜炎（SOM）效果的2b/3期（VOICE）试验完成首次患者给药
February 16, 2021 07:30 ET
|
Monopar Therapeutics Inc.
伊利诺伊州威尔梅特, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc.（纳斯达克股票代码：MNPR）是一家临床阶段生物制药公司，专注于开发延长癌症患者寿命或提高其生活质量的专利疗法。该公司今天宣布，已在Validive®的2b/3期VOICE（prevention of chemoradiotherapy-induced...
Monopar宣布发表论文展示MNPR-101作为改善膀胱癌手术预后的显像剂的应用潜力
February 11, 2021 08:26 ET
|
Monopar Therapeutics Inc.
伊利诺伊州威尔梅特, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc.（Nasdaq：MNPR）是一家临床阶段的生物制药公司，主要专注于开发旨在延长癌症患者寿命并改善其生活质量的专有疗法。该公司今天宣布其一篇同行评议研究的论文在《European Journal of...
Monopar Announces Publication Demonstrating Potential Utility of MNPR-101 as an Imaging Agent to Improve Surgical Outcomes in Bladder Cancer
February 11, 2021 07:30 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics...
Monopar宣布在加拿大发布保护MNPR-101物质成分的专利
February 09, 2021 07:00 ET
|
Monopar Therapeutics Inc.
伊利诺伊州威尔梅特, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc.（Nasdaq：MNPR）是一家临床阶段的生物制药公司，主要专注于开发旨在延长癌症患者寿命并改善其生活质量的专有疗法。该公司今天宣布在加拿大发布保护MNPR-101物质成分的专利，强化了其在包括美国、欧洲和日本在内的全球主要市场的现有保护。 ...
Monopar Announces Issuance of Patent Covering Composition of Matter for MNPR-101 in Canada
February 09, 2021 07:00 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics...
Monopar宣布获发新型Camsirubicin类似物配方的美国专利
December 22, 2020 08:31 ET
|
Monopar Therapeutics Inc.
-所获专利扩大和增强了Monopar目前的camsirubicin知识产权组合-针对晚期软组织瘤的camsirubicin2期试验在2021年初启动的安排保持不变 伊利诺伊州威尔梅特, Dec. 22, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics...
Monopar Announces Issuance of U.S. Patent Covering Compositions of Matter for a Novel Family of Camsirubicin Analogs
December 22, 2020 08:30 ET
|
Monopar Therapeutics Inc.
-Issued patent expands and strengthens Monopar’s existing camsirubicin IP portfolio-Phase 2 initiation for camsirubicin in advanced soft tissue sarcoma remains on track for early 2021 WILMETTE,...
Monopar和NorthStar宣布选定uPRIT候选药物作为重症新冠肺炎潜在治疗药物
December 10, 2020 08:30 ET
|
Monopar Therapeutics Inc.
伊利诺伊州威尔梅特和威斯康星州贝洛伊特, Dec. 10, 2020 (GLOBE NEWSWIRE) -- 合作开发尿激酶型纤溶酶原激活物受体放射免疫疗法（uPRIT）用于重症新冠肺炎患者潜在治疗的Monopar Therapeutics Inc.（Nasdaq: MNPR）和NorthStar Medical Radioisotopes,...